The glycogen synthase kinase inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl- 1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) is a partial agonist of the aryl hydrocarbon receptor

Drug Metabolism and Disposition

Volumn 37, Issue 8, 2009, Pages 1576-1580

  Braeuning, Albert ^a   Buchmann, Albrecht ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; BETA CATENIN; CYTOCHROME P450 1A1; DRUG METABOLIZING ENZYME; GLYCOGEN SYNTHASE KINASE 3BETA; WNT PROTEIN;

ANIMAL CELL; ARTICLE; DRUG MECHANISM; DRUG METABOLISM; ENZYME INDUCTION; HEPATOMA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BETA CATENIN; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; ENZYME INDUCTION; GLYCOGEN SYNTHASE KINASE 3; HEPATOCYTES; INDOLES; MALE; MALEIMIDES; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRACHLORODIBENZODIOXIN; TRANSCRIPTIONAL ACTIVATION; WNT PROTEINS;

EID: 67650792459     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027821     Document Type: Article

References (33)

1. Andrieux L, Langouët S, Fautrel A, Ezan F, Krauser JA, Savouret JF, Guengerich FP, Baffet G, and Guillouzo A (2004) Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes. Mol Pharmacol 65:934-943.
2. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, and Schwarz M (2001) Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 20:7812-7816.
3. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, and Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315.
4. Beischlag TV, Luis Morales J, Hollingshead BD, and Perdew GH (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18:207-250.
5. Braeuning A (2009) Regulation of cytochrome p450 expression by ras- and beta-catenindependent signaling. Curr Drug Metab 10:138-158.
6. Braeuning A, Ittrich C, Köhle C, Buchmann A, and Schwarz M (2007) Zonal gene expression in mouse liver resembles expression patterns of Ha-ras and beta-catenin mutated hepatomas. Drug Metab Dispos 35:503-507.
7. Braeuning A, Sanna R, Huelsken J, and Schwarz M (2009) Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specific knockout of Ctnnb1. Drug Metab Dispos 37:1138-1145.
8. Cao Q, Lu X, and Feng YJ (2006) Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16:671-677.
9. Chesire DR, Dunn TA, Ewing CM, Luo J, and Isaacs WB (2004) Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells. Cancer Res 64:2523-2533.
10. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, et al. (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7:793-803.
11. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
12. De Sarno P, Li X, and Jope RS (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43:1158-1164.
13. Dvorak Z, Vrzal R, Henklova P, Jancova P, Anzenbacherova E, Maurel P, Svecova L, Pavek P, Ehrmann J, Havlik R, et al. (2008) JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem Pharmacol 75:580-588.
14. Evenson AR, Fareed MU, Menconi MJ, Mitchell JC, and Hasselgren PO (2005) GSK-3beta inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int J Biochem Cell Biol 37:2226-2238.
15. Hailfinger S, Jaworski M, Braeuning A, Buchmann A, and Schwarz M (2006) Zonal gene expression in murine liver: lessons from tumors. Hepatology 43:407-414.
16. Hankinson O (1979) Single-step selection of clones of a mouse hepatoma line deficient in aryl hydrocarbon hydroxylase. Proc Natl Acad Sci U S A 76:373-376.
17. Jackson A, Vayssière B, Garcia T, Newell W, Baron R, Roman-Roman S, and Rawadi G (2005) Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36:585-598.
18. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, and Costantini F (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22:1172-1183.
19. Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA, and Reiners JJ Jr (2003) The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metab Dispos 31:1279-1282.
20. Kress S, Reichert J, and Schwarz M (1998) Functional analysis of the human cytochrome P4501A1 (CYP1A1) gene enhancer. Eur J Biochem 258:803-812.
21. Loeppen S, Koehle C, Buchmann A, and Schwarz M (2005) A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 26:239-248.
22. Lustig B and Behrens J (2003) The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129:199-221.
23. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
24. Pottenger LH and Jefcoate CR (1990) Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. Carcinogenesis 11:321-327.
25. Reiners JJ Jr, Lee JY, Clift RE, Dudley DT, and Myrand SP (1998) PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol 53:438-445.
26. Schreiber TD, Köhle C, Buckler F, Schmohl S, Braeuning A, Schmiechen A, Schwarz M, and Münzel PA (2006) Regulation of CYP1A1 gene expression by the antioxidant tertbutylhydroquinone. Drug Metab Dispos 34:1096-1101.
27. Sekine S, Lan BY, Bedolli M, Feng S, and Hebrok M (2006) Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology 43:817-825.
28. Stahl S, Ittrich C, Marx-Stoelting P, Köhle C, Altug-Teber O, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, et al. (2005) Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 42:353-361.
29. Stambolic V, Ruel L, and Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6:1664-1668.
30. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol Chemother 11:379-393.
31. Tan X, Behari J, Cieply B, Michalopoulos GK, and Monga SP (2006) Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131:1561-1572.
32. Willert K and Nusse R (1998) Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 8:95-102.
33. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M, and Hirohashi S (2003) Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 37:528-533.